Search research articles
Contact Us
Filters
Showing results (41-50 of 99) with videos related to
Page
of 10
Sort By:
Clinical & Translational Immunology
|
February 28, 2018
Characterisation of anti-alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against <i>Staphylococcus aureus</i> alpha toxin
Alexey Ruzin, Yuling Wu, Li Yu, et al.
Acta Obstetricia Et Gynecologica Scandinavica
|
October 19, 2007
Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics
Finn Egil Skjeldestad, Vinay Mehta, Heather L Sings, et al.
Infectious Diseases and Therapy
|
February 25, 2024
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial
F D Richard Hobbs, Hugh Montgomery, Francisco Padilla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 1, 2008
Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia
Anthony T Newall, Julia M L Brotherton, Helen E Quinn, et al.
Clinical & Translational Immunology
|
June 14, 2024
Serum AZD7442 (tixagevimab-cilgavimab) concentrations and <i>in vitro</i>IC<sub>50</sub> values predict SARS-CoV-2 neutralising antibody titres
Lindsay E Clegg, Oleg Stepanov, Sam Matthews, et al.
Journal of Clinical Microbiology
|
October 22, 2020
Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017-2018 INFORM-RSV Study
David E Tabor, Fiona Fernandes, Annefleur C Langedijk, et al.
Clinical & Translational Immunology
|
July 31, 2019
Associations of pathogen-specific and host-specific characteristics with disease outcome in patients with <i>Staphylococcus aureus</i> bacteremic pneumonia
Batu K Sharma-Kuinkel, Christine Tkaczyk, Jessica Bonnell, et al.
Plos One
|
July 25, 2018
Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States
Alexey Ruzin, Susan T Pastula, Elizabeth Levin-Sparenberg, et al.
The Pediatric Infectious Disease Journal
|
May 9, 2007
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial
Keith S Reisinger, Stan L Block, Eduardo Lazcano-Ponce, et al.
International Journal of Cancer
|
November 15, 2007
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women
Gonzalo Perez, Eduardo Lazcano-Ponce, Mauricio Hernandez-Avila, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 99) with videos related to
Sort By:
Page
of 10
Clinical & Translational Immunology
|
February 28, 2018
Characterisation of anti-alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against <i>Staphylococcus aureus</i> alpha toxin
Alexey Ruzin, Yuling Wu, Li Yu, et al.
Acta Obstetricia Et Gynecologica Scandinavica
|
October 19, 2007
Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics
Finn Egil Skjeldestad, Vinay Mehta, Heather L Sings, et al.
Infectious Diseases and Therapy
|
February 25, 2024
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial
F D Richard Hobbs, Hugh Montgomery, Francisco Padilla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 1, 2008
Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia
Anthony T Newall, Julia M L Brotherton, Helen E Quinn, et al.
Clinical & Translational Immunology
|
June 14, 2024
Serum AZD7442 (tixagevimab-cilgavimab) concentrations and <i>in vitro</i>IC<sub>50</sub> values predict SARS-CoV-2 neutralising antibody titres
Lindsay E Clegg, Oleg Stepanov, Sam Matthews, et al.
Journal of Clinical Microbiology
|
October 22, 2020
Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017-2018 INFORM-RSV Study
David E Tabor, Fiona Fernandes, Annefleur C Langedijk, et al.
Clinical & Translational Immunology
|
July 31, 2019
Associations of pathogen-specific and host-specific characteristics with disease outcome in patients with <i>Staphylococcus aureus</i> bacteremic pneumonia
Batu K Sharma-Kuinkel, Christine Tkaczyk, Jessica Bonnell, et al.
Plos One
|
July 25, 2018
Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States
Alexey Ruzin, Susan T Pastula, Elizabeth Levin-Sparenberg, et al.
The Pediatric Infectious Disease Journal
|
May 9, 2007
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial
Keith S Reisinger, Stan L Block, Eduardo Lazcano-Ponce, et al.
International Journal of Cancer
|
November 15, 2007
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women
Gonzalo Perez, Eduardo Lazcano-Ponce, Mauricio Hernandez-Avila, et al.
Page
of 10